ClinicalTrials.gg
RecruitingNCT07710872Updated Oct 19, 2026

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China

A Phase 3 interventional study of MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA) and Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) in Meningococcal Infection and Healthy Volunteers, sponsored by Sanofi. Recruiting at 8 sites in China. Open to participants aged 2 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 19, 20264 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,568
Allocation
Randomized
Ages
2 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Meningococcal Infections by Sanofi — 2 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Sanofi.

Planned enrollment
Largest of 51
4,568 · median 378
Started
2026
the only one that year
Phase 3
25 of 57
1 open now
Registered
57th of 57
by date

Among the 57 studies in Meningococcal Infections by Sanofi, this one has the largest planned enrollment of the 51 interventional ones that give a count, is the only one that started in 2026, is one of 25 in phase 3, and was the 57th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

2 of the 57 studies in Meningococcal Infections by Sanofi are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 2 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Meningococcal Infections by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China.

Study details include:

  • Study duration (including 6-month safety follow-up after the last dose):
  • Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months)
  • Cohort II (Groups 3 and 4): up to 18 months
  • Cohort III (Groups 5 and 6): up to 21 months
  • Cohort III (Group 7): approximately 16 months
  • Vaccination Visits Period:
  • Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91).

Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit for safety follow-up. For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.

- Cohort II (Groups 3 and 4): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). A 1-dose booster is planned for Group 3 only at 18 MoA (within the 18th month from the participant's birth date).

Up to 4 blood samples will be collected. In the primary vaccination period, blood samples are collected before the first primary vaccination (D01) and 30 days post the 2nd dose of primary vaccination (D61 or D121). A blood sample will be collected from all participants at 18 MoA. A post-booster blood sample will be collected from participants in Group 3, 30 days post their booster vaccination.

Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods, respectively, for safety follow-up.

For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.

- Cohort III - Groups 5 and 6: a 3-dose primary vaccination at V01 (D01), V02 (D31) and V03 (D61), a 1-dose booster at 12 MoA (within the 12th months from the participant's birth date) on V05 or at 18 MoA (within the 18th months from the participant's birth date) on V06.

In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D91); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 (for participants receiving the booster at 12 MoA) or V06 (for participants receiving the booster at 18 MoA), and 30 days post booster vaccination (V05 + 30 days or V06 + 30 days).

Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods respectively for safety follow-up.

- Cohort III - Group 7: a 3-dose primary vaccination at V01 (D01), V02 (D61) and V03 (D121), a 1-dose booster at V05 at 12 MoA (within the 12th months from the participant's birth date).

In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D151); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 and 30 days post booster vaccination (V06).

Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods (ie, V04 and V06), respectively, for safety follow-up. A safety visit is planned on the 9th day after the first vaccination for the ESDR participants (the first 30 participants in this group).

03

Conditions studied

  • Meningococcal Infection
  • Healthy Volunteers
04

Who can participate

Ages eligible
2 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Cohort I: Aged 12 months through 23 months on the day of inclusion. For Cohort II: Aged 6 months through 11 months on the day of inclusion. For Cohort III: Aged 2 months through 5 months on the day of inclusion
  • Born at full term of pregnancy (≥37 weeks) or born after a gestation period of 27 through 36 weeks and medically stable as assessed by the investigator
  • form has been signed and dated by the parent(s) or other LAR (and by an independent witness if required by local regulations).
  • Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy; or long-term systemic therapy
  • History of meningococcal infection
  • History of any neurological disorders
  • History of Guillain-Barré syndrome
  • History of an Arthus-type reaction after a previous dose of tetanus toxoid-containing vaccine
  • At high risk for meningococcal infection during the study
  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
  • Self-reported thrombocytopenia, contraindicating intramuscular injection
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C [99.5℉]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Receipt of any within 14 days preceding the trial vaccination or planned receipt of any live vaccines in 14 days following trial vaccination, and receipt of any inactivated vaccines in 8 days preceding the trial vaccination or planned receipt of any live vaccines in 8 days following trial vaccination
  • For Cohort I (12 to 23 MoA): receipt of any other meningococcal vaccine except the meningococcal group A polysaccharide vaccine included in the NIP. The time since last vaccination of meningococcal group A or groups A and C polysaccharide vaccine of 6 months or less should be excluded.
  • For Cohorts II (6 to 11 MoA) and III (2 to 5 MoA): a vaccination history of any meningococcal vaccine.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Participation at the time of study enrollment (or in the 4 weeks preceding the study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
  • In an emergency setting, or being hospitalized
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,568 participants (estimated)

Study arms

  • Experimental
    Cohort I: Group 1MenACYW 2-dose schedule

    2 doses of MenACYW conjugate vaccine to participants aged 12 through 23 MoA

    Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)

  • Active comparator
    Cohort I: Group 2 MenACYW135, CanSino 2-dose schedule

    2 doses of MenACYW135, CanSino conjugate vaccine to participants aged 12 through 23 MoA

    Biological: Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)

  • Experimental
    Cohort II: Group 3MenACYW 2-dose primary vaccination + 1-dose booster schedule

    2-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 6 through 11 MoA

    Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)

  • Active comparator
    Cohort II: Group 4 MenACYW135, CanSino 2-dose schedule

    2-dose primary vaccination and 1-dose booster of MenACYW135, CanSino conjugate vaccine to participants aged 6 through 11 MoA

    Biological: Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)

  • Experimental
    Cohort III: Group 5 MenACYW 3-dose primary vaccination + 1-dose booster schedule

    3-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 3 through 5 MoA

    Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)

  • Active comparator
    Cohort III: Group 6 MenACYW135, CanSino 3-dose primary vaccination + 1-dose booster schedule

    3-dose primary vaccination and 1-dose booster of MenACYW135, CanSino conjugate vaccine to participants aged 3 through 5 MoA

    Biological: Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)

  • Experimental
    Cohort III: Group 7 MenACYW 3-dose primary vaccination + 1-dose booster schedule

    3-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 2 MoA

    Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)

Interventions

  • BiologicalMenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)

    Pharmaceutical form:Liquid solution-Route of administration:IM injection

  • BiologicalMenhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)

    Pharmaceutical form:Lyophilized powder (MenAC conjugate vaccine) and liquid solution (MenYW135 conjugate vaccine)-Route of administration:IM injection

06

What researchers measure

Primary outcomes

  1. Participants 12 through 23 MoA (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W

    30 days post-2nd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-2nd vaccination for participants with pre-vaccination rSBA titer ≥1:8

    Time frame: 30 days post 2nd vaccination (up to Day 121)

  2. Participants 12 through 23 MoA (Cohort I): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W measured by rSBA

    30 days (+10 days) post-2nd vaccination with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine

    Time frame: 30 days post 2nd vaccination (up to Day 121)

  3. Participants 6 through 11 MoA (Cohort II): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W

    30 days post-2nd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-2nd vaccination for participants with pre-vaccination rSBA titer ≥1:8

    Time frame: 30 days post 2nd vaccination (up to Day 121)

  4. Participants 6 through 11 MoA (Cohort II): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA

    30 days (+10 days) post-2nd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine

    Time frame: 30 days post 2nd vaccination (up to Day 121)

  5. Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W

    30 days post-3rd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-3rd vaccination for participants with pre-vaccination rSBA titer ≥1:8

    Time frame: Day 91

  6. Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA

    30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine

    Time frame: Day 91

  7. Participants 2 through 5 MoA (Cohort III - Groups 7 and 6): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W

    30 days post-3rd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-3rd vaccination for participants with pre-vaccination rSBA titer ≥1:8

    Time frame: Day 151

  8. Participants 2 through 5 MoA (Cohort III - Groups 7 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA

    30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine (Group 7) or MenACYW135, CanSino conjugate vaccine (Group 6)

    Time frame: Day 151

Secondary outcomes

  1. Number of participants with immediate adverse events (AEs)

    Unsolicited systemic AEs that occur within 30 minutes after vaccination

    Time frame: Within 30 minutes post-vaccination

  2. Presence of solicited injection site reactions

    (pre-listed in the participant diary and CRF)

    Time frame: for 8 days, including the day of each study vaccination.

  3. Presence of solicited systemic reactions

    (pre-listed in the participant diary and CRF)

    Time frame: for 8 days, including the day of each study vaccination.

  4. Presence of unsolicited AEs

    Time frame: for 30 days including the day of each study vaccination.

  5. Presence of SAEs

    Time frame: Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7

  6. Presence of AEs leading to study discontinuation

    Time frame: Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7

  7. Participants 12 through 23 MoA (Cohort I) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) post-2nd vaccination with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine.

    Time frame: 30 days post 2nd vaccination (up to Day 121)

  8. Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA

    30 days (+10 days) post-2nd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine.

    Time frame: 30 days post 2nd vaccination (up to Day 121)

  9. Participants 6 through 11 MoA (Cohort II) Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 18 MoA.

    Time frame: at 18 MoA (up to Day 394)

  10. Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA pre-booster dose at 18 MoA

    Time frame: at 18 MoA (up to Day 394)

  11. Participants 6 through 11 MoA (Cohort II) Antibody titers (in terms of GMTs) against booster meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine given at 18 MoA.

    Time frame: at 18 MoA (up to Day 424)

  12. Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) after one dose of booster vaccination of MenACYW conjugate vaccine

    Time frame: at 18 MoA (up to Day 424)

  13. Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA

    30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine.

    Time frame: D91

  14. Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA

    pre-booster dose at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine

    Time frame: at 12 and 18 MoA (up to Day 484)

  15. Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA

    pre-booster dose at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine

    Time frame: at 12 and 18 MoA (up to Day 484)

  16. Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA

    30 days (+10 days) post-booster vaccination at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine

    Time frame: 30 days after 12 and 18 MoA (up to Day 514)

  17. Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA

    30 days (+10 days) post-booster vaccination at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine

    Time frame: 30 days after 12 and 18 MoA (up to Day 514)

  18. Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine (Group 7).

    Time frame: D151

  19. Participants 2 MoA (Cohort III - Group 7): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 12 MoA (Group 7) with MenACYW conjugate vaccine

    Time frame: at 12 MoA (up to Day 333)

  20. Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 12 MoA (Group 7) with MenACYW conjugate vaccine

    Time frame: at 12 MoA (up to Day 333)

  21. Participants 2 MoA (Cohort III - Group 7): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine at 12 MoA (Group 7)

    Time frame: 30 days after 12 MoA (up to Day 363)

  22. Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine at 12 MoA (Group 7)

    Time frame: 30 days after 12 MoA (up to Day 363)

07

Study locations

8 of 8 sites recruiting
  • Investigational Site Number : 1563001
    Huanggang, 435300, China
    Recruiting
  • Investigational Site Number : 1563003
    Jianli City, Jingzhou City, 433300, China
    Recruiting
  • Investigational Site Number : 1561001
    Jingxi, 533899, China
    Recruiting
  • Investigational Site Number : 1561003
    Liuzhou, 545100, China
    Recruiting
  • Investigational Site Number : 1561000
    Nanning, NaN, China
    Recruiting
  • Investigational Site Number : 1561002
    Tengzhou Town, 543399, China
    Recruiting
  • Investigational Site Number : 1563000
    Wuhan, 430079, China
    Recruiting
  • Investigational Site Number : 1563002
    Xiangyang City, Hubei Province, 441199, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's planned 18 months is above that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartActual
Aug 22, 2026
Primary completionEst.
Mar 13, 2028
CompletionEst.
Jul 26, 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added
Show 4 added (4 China)
  • Investigational Site Number : 1563001 · Huanggang, China
  • Investigational Site Number : 1563003 · Jianli City, Jingzhou City, China
  • Investigational Site Number : 1563000 · Wuhan, China
  • Investigational Site Number : 1563002 · Xiangyang City, Hubei Province, China
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    4 sites added
    Show 4 added (4 China)
    • Investigational Site Number : 1563001 · Huanggang, China
    • Investigational Site Number : 1563003 · Jianli City, Jingzhou City, China
    • Investigational Site Number : 1563000 · Wuhan, China
    • Investigational Site Number : 1563002 · Xiangyang City, Hubei Province, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07710872
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Aug 22, 2026
Primary completion
Mar 13, 2028 (estimated)
Completion
Jul 26, 2029 (estimated)
Last update
Oct 19, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion